Anti-maa immunoglobulin isotypes in inflammatory bowel disease: novel diagnostic implications for ulcerative colitis
AssigneeBoard of Regents of the University of Nebraska
InventorsGeoffrey M. Thiele, Amar Singh, Michael J. Duryee, Rizwan Ahmad
Life of this patent
Estimating the term…
Abstract
In various embodiments methods of distinguishing Crohn's disease from ulcerative colitis are provided. In certain embodiments the methods comprise determining, or causing to be determined, the level of IgG antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from a mammal, where an elevated level of said antibodies as compared to the average level found in a mammal with Crohn's disease is an indicator that the mammal has ulcerative colitis rather than Crohn's disease
Claims21
-112. (canceled)
A method of treating a subject, the method comprising:
- detecting a level of antibodies that bind a malondialdehyde-acetaldehyde (MAA) adduct in a biological sample of a subject having at least one symptom of ulcerative colitis or Crohn's disease;
- comparing the level of the antibodies that bind the MAA adduct to an average level in another subject with the Crohn's disease;
- determining that the level of the antibodies that bind the MAA adduct is higher than the average level in the other subject with the Crohn's disease;
- identifying the subject as having the ulcerative colitis;
- and
- administering a pharmaceutical to the subject to treat the ulcerative colitis.
A method of treating a subject, the method comprising:
- detecting a level of antibodies that bind a malondialdehyde-acetaldehyde (MAA) adduct and a level of at least one inflammatory biomarker in a biological sample of a subject having at least one symptom of ulcerative colitis or Crohn's disease;
- comparing the level of the antibodies that bind the MAA adduct to an average level in another subject with the Crohn's disease;
- comparing the level of the at least one inflammatory biomarker to an average level of the at least one inflammatory biomarker in the other subject with the Crohn's disease;
- determining that the level of the antibodies that bind the MAA adduct is higher than the average level in the other subject with the Crohn's disease;
- determining that the level of the at least one inflammatory biomarker is higher than the average level in the other subject with the Crohn's disease;
- identifying the subject as having the ulcerative colitis;
- and
- administering a pharmaceutical to the subject to treat the ulcerative colitis.
Dependencies are inferred from the claim text.